Are you sure?

Sanofi to curtail R&D activity at Hungarian subsidiary

Paris-based pharmaceutical company Sanofi will eliminate first-phase R&D activity at its Hungarian subsidiary Chinoin, the latter company’s Communications Director Iván Rózsa told MTI on Tuesday evening.

The move is part of global restructuring of R&D activities within the Sanofi group, he said.

Rózsa emphasized that Chinoin would continue to conduct later-phase R&D activity in the country. These could bear results more rapidly and are export-oriented, he said.

The elimination of initial-phase R&D activity will affect 160 employees at Chinoin, Rózsa said.